David V Gauvin
Overview
Explore the profile of David V Gauvin including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
40
Citations
93
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Gauvin D, McComb M, Farero R
Int J Toxicol
. 2023 Dec;
43(2):196-208.
PMID: 38151260
This commentary discusses the implementation of fasting in nonclinical animal experimental subjects. The short-term removal of food from cages of experimental animals is in all respects innocuous. The term "stress"...
2.
3.
Distortion Product Otoacoustic Emission Test is Not the Test to Use in Nonclinical Safety Assessment
Gauvin D, McComb M, Tapp R, Yoder J, Zimmermann Z
Int J Toxicol
. 2022 Apr;
41(3):243-252.
PMID: 35443823
Ototoxicity and ocular toxicity screening are but two examples of specialty product lines that are often employed as Tier II or III nonclinical safety/hazard screening assessments. Compared to the regulatory...
4.
Gauvin D, Zimmermann Z, Dalton J
Regul Toxicol Pharmacol
. 2022 Jan;
129:105116.
PMID: 35017023
Derisking is not a pharmaceutical industry strategy to reduce time, effort, or costs in drug development. Derisking strategies originated within the National Institutes of Health as a predicate to good...
5.
Asakura S, Shiotani M, Gauvin D, Fujiwara A, Ueno T, Bower N, et al.
Regul Toxicol Pharmacol
. 2021 Oct;
127:105053.
PMID: 34619288
Lemborexant is a dual orexin receptor antagonist (DORA) approved in multiple countries including the United States, Japan, Canada and Australia for the treatment of adults with insomnia. As required for...
6.
Gauvin D, Zimmermann Z
J Pharmacol Toxicol Methods
. 2021 May;
111:107073.
PMID: 33965568
This "methods paper" focusses on one specific and limited aspect of drug safety evaluations required for all new drug entities that affect the central nervous system - the drug discrimination...
7.
Gauvin D, Zimmermann Z, Dalton J, Baird T, Kallman M
Int J Toxicol
. 2019 Sep;
38(5):339-356.
PMID: 31470748
In the adoption of behavior as a critical end point in safety pharmacology and neurotoxicity screening, federal regulatory agencies have shifted the predominating scientific perspective from pharmacology back to the...
8.
Gauvin D, Zimmermann Z, Yoder J, Tapp R, Baird T
Int J Toxicol
. 2019 Jun;
38(4):265-278.
PMID: 31220989
History has established that many drugs, such as the antibiotics, chemotherapies, and loop diuretics, are capable of inducing both nephrotoxicity and ototoxicity. The exact mechanisms by which cellular damage occurs...
9.
Baird T, Caruso M, Gauvin D, Dalton J
J Pharmacol Toxicol Methods
. 2019 Jun;
99:106597.
PMID: 31220592
Introduction: The concept of characterizing adversity in relation to administered test article dose and/or exposure within toxicology studies has long been considered a normal aspect of the drug safety evaluation...
10.
Gauvin D, Zimmermann Z, Dalton J, Baird T
J Pharmacol Toxicol Methods
. 2019 Jun;
99:106594.
PMID: 31158458
The standard infrared photobeam locomotor activity system has been used extensively in neurobiology and neuropharmacology to study the functional impact of direct manipulations of the nervous system. There is interest...